Get the Stockscreener App
2.34
2.64%
0.07
Tuhura Biosciences Inc stock is traded at $2.34, with a volume of 320.02K.
It is up +2.64% in the last 24 hours and up +22.63% over the past month.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
See More
Previous Close:
$2.27
Open:
$2.26
24h Volume:
320.02K
Relative Volume:
0.20
Market Cap:
$146.87M
Revenue:
-
Net Income/Loss:
$-30.05M
P/E Ratio:
-3.709
EPS:
-0.6309
Net Cash Flow:
$-27.71M
1W Performance:
+60.69%
1M Performance:
+22.63%
6M Performance:
-4.12%
1Y Performance:
-44.79%
1-Day Range:
$2.2441
$2.3817
1-Week Range:
$1.27
$2.3817
52-Week Range:
$0.41
$4.44
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.31 | 144.32M | 0 | -30.05M | -27.71M | -0.6309 |
VRTX
Vertex Pharmaceuticals Inc
|
443.37 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.46 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
804.94 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
324.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.84 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
HURA.O PE Ratio & Valuation, Is HURA.O Overvalued - Intellectia AI
Aug Rallies: Does TuHURA Biosciences Inc. align with a passive investing strategyTrade Volume Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
Hedge Fund Moves: Is TuHURA Biosciences Inc a strong candidate for buy and hold - baoquankhu1.vn
HURA: 2025 Financial Results - Yahoo Finance
TuHURA Biosciences Acquires Kineta in $16.6M Merger and Closes $12.6M Private Placement – Key Details and Financial Impact - Minichart
TuHURA Biosciences approves executive bonuses and salary increases By Investing.com - Investing.com India
TuHURA Biosciences Approves 2025 Executive Compensation Adjustments - TipRanks
TuHURA Biosciences approves executive bonuses and salary increases - Investing.com
Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co. - TradingView — Track All Markets
TuHURA awards bonuses to James Bianco and Dan Dearborn, adjusts salaries - TradingView
TuHURA Appoints New SVP of Clinical Operations - Intellectia AI
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP By Investing.com - Investing.com South Africa
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP - Investing.com
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations - bitget.com
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
HURA SEC FilingsTuHURA Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Risk: What dividend growth rate does TuHURA Biosciences Inc offer2026 Closing Moves & Detailed Earnings Play Strategies - baoquankhu1.vn
EPS Watch: Does TuHURA Biosciences Inc stock reflect fundamentals2026 Technical Patterns & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
TuHURA Biosciences, Inc. (NASDAQ:HURA): Is Breakeven Near? - Sahm
TuHURA Biosciences, Inc. (HURA) stock price, news, quote and history - Yahoo Finance UK
TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit - Yahoo Finance
TuHURA Biosciences Reports 2025 Financial Results, Advances Phase 3 Cancer Trials and Expands Pipeline with VISTA Antibody Acquisition - Minichart
Tuhura Biosciences reports fourth quarter and full year 2025 financial results and provides a corporate update - marketscreener.com
Tuhura Biosciences Reports Fourth Quarter And Full Year 2025 Financial Results And Provides A Corporate Update - TradingView
TuHURA (Nasdaq: HURA) ramps R&D as IFx-2.0 enters Phase 3 - Stock Titan
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - PR Newswire
TuHURA says Merkel cell cancer Phase 3 enrollment ends mid-2027 - Stock Titan
TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
TuHURA Biosciences (NASDAQ: HURA) maps Phase 3 trial and AML plans - Stock Titan
TuHURA R&D Jumps 75% in Q2 - AOL.com
Volatility Watch: Is TuHURA Biosciences Inc exposed to political riskDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
TuHURA Biosciences, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
TuHURA Biosciences (NASDAQ:HURA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
TuHURA Biosciences Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Layoff Watch: Does TuHURA Biosciences Inc. align with a passive investing strategyEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn
TuHURA Biosciences, Inc. Common Stock (HURA) Stock Price Today & Analysis - Gotrade
TuHURA Biosciences appoints Craig Tendler as chief medical officer By Investing.com - Investing.com Australia
TuHURA Biosciences, Inc.Common Stock (NQ: HURA - The Chronicle-Journal
TuHURA Biosciences appoints Craig Tendler as chief medical officer - Investing.com
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers - ChartMill
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Growth Report: How is TuHURA Biosciences Inc managing supply chain issuesWeekly Earnings Recap & Consistent Growth Equity Picks - baoquankhu1.vn
HURA Earnings History & Surprises | EPS & Revenue Results | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Bull Bear: Is TuHURA Biosciences Inc a strong candidate for buy and hold2026 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Moving Averages: Is TuHURA Biosciences Inc attractive for institutional investorsPortfolio Growth Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Wall Street Zen Upgrades TuHURA Biosciences (NASDAQ:HURA) to "Hold" - MarketBeat
TuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1%Here's Why - MarketBeat
Market Rankings: What dividend growth rate does TuHURA Biosciences Inc offerTrade Entry Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
HURA Should I Buy - Intellectia AI
Aug PostEarnings: Will TuHURA Biosciences Inc outperform its industry peersPortfolio Gains Report & Capital Efficiency Focused Ideas - baoquankhu1.vn
Tuhura Biosciences Inc Stock (HURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):